• Revive set a biodefense, pandemic-preparedness development strategy centered on bucillamine, following positive Canadian DRDC preclinical results.
• In a nerve-agent animal model, bucillamine matched N-acetylcysteine on a hippocampal GABA receptor endpoint.
• No pulmonary hemorrhage appeared in bucillamine-treated animals, versus pulmonary hemorrhage in the N-acetylcysteine group.
• Confirmatory DRDC studies are scheduled to start in Q4 2026, shaping indication selection, regulatory planning, partnering, procurement pathways.
• Patent position cited includes Canadian Patent No. 3,172,170, with an expiry date stated as March 16, 2041.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revive Therapeutics Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608190840ACCESSWRNAPR_____1209216) on August 19, 2026, and is solely responsible for the information contained therein.